0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Multiple Myeloma -Epidemiology Forecast to 2028
Published Date: March 2019
|
Report Code: DELV-Epid-427
Home | Market Reports |Health |Health Conditions |Cancer
Multiple Myeloma Epidemiology Forecast to 2028

Multiple Myeloma -Epidemiology Forecast to 2028

Code: DELV-Epid-427
Report
March 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Multiple Myeloma - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Multiple Myeloma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Multiple Myeloma Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Multiple Myeloma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Multiple Myeloma outlook. It also includes the explanation of changing trends of epidemiology outlining the Multiple Myeloma scenario.

Multiple Myeloma Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Multiple Myeloma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Multiple Myeloma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Multiple Myeloma Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Multiple Myeloma

Key assessments
• Patient Segmentation in Multiple Myeloma
• Multiple Myeloma Risk & Burden
• Factors driving growth in a specific Multiple Myeloma patient population

1. Report Introduction
2. Multiple Myeloma Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Multiple Myeloma in 2016
2.2. Patient Share Distribution of Multiple Myeloma in 2028
3. Disease Background and Overview: Multiple Myeloma
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Multiple Myeloma in 7MM
4.3. Total Prevalent/ Incident Patient Population of Multiple Myeloma in 7MM – By Countries
5. Epidemiology of Multiple Myeloma by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Multiple Myeloma
5.1.3. Sub-Type Specific cases of the Multiple Myeloma *
5.1.4. Sex- Specific Cases of the Multiple Myeloma*
5.1.5. Diagnosed Cases of the Multiple Myeloma
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Multiple Myeloma
5.4.3. Sub-Type Specific cases of the Multiple Myeloma*
5.4.4. Sex- Specific Cases of the Multiple Myeloma*
5.4.5. Diagnosed Cases of the Multiple Myeloma
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Multiple Myeloma
5.5.3. Sub-Type Specific cases of the Multiple Myeloma*
5.5.4. Sex- Specific Cases of the Multiple Myeloma*
5.5.5. Diagnosed Cases of the Multiple Myeloma
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Multiple Myeloma
5.6.3. Sub-Type Specific cases of the Multiple Myeloma*
5.6.4. Sex- Specific Cases of the Multiple Myeloma*
5.6.5. Diagnosed Cases of the Multiple Myeloma
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Multiple Myeloma
5.7.3. Sub-Type Specific cases of the Multiple Myeloma*
5.7.4. Sex- Specific Cases of the Multiple Myeloma*
5.7.5. Diagnosed Cases of the Multiple Myeloma
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Multiple Myeloma
5.8.3. Sub-Type Specific cases of the Multiple Myeloma*
5.8.4. Sex- Specific Cases of the Multiple Myeloma*
5.8.5. Diagnosed Cases of the Multiple Myeloma
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Multiple Myeloma
5.9.3. Sub-Type Specific cases of the Multiple Myeloma*
5.9.4. Sex- Specific Cases of the Multiple Myeloma*
5.9.5. Diagnosed Cases of the Multiple Myeloma
6. Unmet Needs of the Multiple Myeloma
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM
Table 2: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Multiple Myeloma in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Multiple Myeloma in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Multiple Myeloma in United States (2016-2028)*
Table 6: Diagnosed Cases of the Multiple Myeloma in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Multiple Myeloma in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Multiple Myeloma in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Multiple Myeloma in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Multiple Myeloma in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Multiple Myeloma in France (2016-2028)
Table 12: Sub-Type Specific cases of the Multiple Myeloma in France (2016-2028) *
Table 13: Sex- Specific Cases of the Multiple Myeloma in France (2016-2028) *
Table 14: Diagnosed Cases of the Multiple Myeloma in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Multiple Myeloma in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Multiple Myeloma in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Multiple Myeloma in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Multiple Myeloma in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Multiple Myeloma in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Multiple Myeloma in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Multiple Myeloma in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Multiple Myeloma in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Multiple Myeloma in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Multiple Myeloma in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Multiple Myeloma in UK (2016-2028) *
Table 26: Diagnosed Cases of the Multiple Myeloma in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Multiple Myeloma in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Multiple Myeloma in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Multiple Myeloma in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Multiple Myeloma in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM
Figure 2: Total Prevalent/Incident Cases of the Multiple Myeloma in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Multiple Myeloma in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Multiple Myeloma in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Multiple Myeloma in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Multiple Myeloma in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Multiple Myeloma in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Multiple Myeloma in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Multiple Myeloma in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Multiple Myeloma in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Multiple Myeloma in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Multiple Myeloma in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Multiple Myeloma in France (2016-2028) *
Figure 14: Diagnosed Cases of the Multiple Myeloma in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Multiple Myeloma in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Multiple Myeloma in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Multiple Myeloma in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Multiple Myeloma in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Multiple Myeloma in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Multiple Myeloma in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Multiple Myeloma in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Multiple Myeloma in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Multiple Myeloma in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Multiple Myeloma in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Multiple Myeloma in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Multiple Myeloma in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Multiple Myeloma in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Multiple Myeloma in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Multiple Myeloma in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Multiple Myeloma in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
SIS Group of Schools

RELATED REPORTS

Global Cisplatin API Sales Market Report 2021
Global Cisplatin API Sales Market Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-11R4997
Wed Jun 16 00:00:00 UTC 2021

Add to Cart

Global Cervical Cancer Treatment Sales Market Report 2021
Global Cervical Cancer Treatment Sales Market Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-23A5100
Wed Jun 16 00:00:00 UTC 2021

Add to Cart

Global Liposomal Doxorubicin Market Insights and Forecast to 2027
Global Liposomal Doxorubicin Market Insights and Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-38O5182
Wed Jun 16 00:00:00 UTC 2021

Add to Cart

Global Palonosetron Hydrochloride Sales Market Report 2021
Global Palonosetron Hydrochloride Sales Market Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-5L5009
Wed Jun 16 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0